# Differences in the aggressiveness of familial versus sporadic non-medullary thyroid cancer: An unresolved controversy

**Authors:** Fabíola Yukiko Miasaki, Teresa Cristina Santos Cavalcanti, Hans Graf, Edna Teruko Kimura, Peter Andreas Kopp, Gisah Amaral de Carvalho

PMC · DOI: 10.20945/2359-4292-2026-0018 · 2026-02-16

## TL;DR

This study compares the aggressiveness of familial and sporadic non-medullary thyroid cancer, finding that familial cases tend to occur at a younger age and with more lymph node involvement.

## Contribution

The study provides new evidence on the clinical differences between familial and sporadic non-medullary thyroid cancer, including younger age at diagnosis and higher metastasis rates in familial cases.

## Key findings

- FNMTC patients were diagnosed at a younger age compared to SNMTC patients.
- FNMTC patients had a 4.57-fold increased risk of lymph node metastases at diagnosis.
- Long-term outcomes did not differ significantly between FNMTC and SNMTC groups.

## Abstract

Familial non-medullary thyroid cancer (FNMTC) is defined as non-medullary
thyroid cancer occurring in two or more first-degree relatives, without
features of known hereditary syndromes. Although familial predisposition is
well established, its clinical behavior remains debated. This study aimed at
characterizing familial cases compared to sporadic non-medullary thyroid
cancer (SNMTC).

FNMTC and SNMTC patients were recruited from the Endocrine Division (SEMPR)
of the Federal University of Paraná, Brazil, and private endocrine
clinics in Curitiba, Paraná, Brazil (2000-2019). Baseline,
histopathological, and clinical data were analyzed using SPSS Statistics
26.0. Statistical comparisons employed chi-square, Student’s t test, and
Mann-Whitney U test, as appropriate. Post hoc power analysis was performed
using G*Power 3.1.9.7, and R 2025.05.0.

We analyzed 39 FNMTC and 119 SNMTC patients. Papillary thyroid carcinoma was
the predominant histological type in both groups. FNMTC patients were
diagnosed at a younger age (38.5 ± 14.2 vs. 46.6 ± 13.8 years,
p = 0.003) and more frequently presented with lymph node metastases at
diagnosis (46.2% vs. 21.8%, p = 0.007), with a 4.57-fold increased risk.
Despite these differences, long-term outcomes did not differ significantly
between groups. An earlier disease onset in subsequent generation suggests a
possible anticipation phenomenon.

These findings suggest that FNMTC patients may present with earlier onset and
higher rates of lymph node involvement, underscoring the need for thorough
preoperative lateral neck evaluation. In view of a possible anticipation
phenomenon, cervical ultrasound screening might be considered starting in
adolescence.

## Linked entities

- **Diseases:** papillary thyroid carcinoma (MONDO:0005075)

## Full-text entities

- **Genes:** NKX2-1 (NK2 homeobox 1) [NCBI Gene 7080] {aka BCH, BHC, NK-2, NKX2.1, NKX2A, NMTC1}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, POT1 (protection of telomeres 1) [NCBI Gene 25913] {aka CMM10, CRMCC3, GLM9, HPOT1, PFBMFT8, TPDS3}, PTCPRN (Papillary thyroid carcinoma with papillary renal neoplasia) [NCBI Gene 79052] {aka PRN1}, SRRM2 (serine/arginine repetitive matrix 2) [NCBI Gene 23524] {aka 300-KD, CWF21, Cwc21, HSPC075, MRD72, SRL300}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, NMTC3 (Nonmedullary thyroid carcinoma 3) [NCBI Gene 114568] {aka NMTC1}, TINF2 (TERF1 interacting nuclear factor 2) [NCBI Gene 26277] {aka DKCA3, DKCA5, TIN2}, SRGAP1 (SLIT-ROBO Rho GTPase activating protein 1) [NCBI Gene 57522] {aka ARHGAP13, NMTC2}, PRKAR1A (protein kinase cAMP-dependent type I regulatory subunit alpha) [NCBI Gene 5573] {aka ACRDYS1, ADOHR, CAR, CNC, CNC1, PKR1}, TCO (Thyroid carcinoma, nonmedullary, with cell oxyphilia) [NCBI Gene 50975], ACD (ACD shelterin complex subunit and telomerase recruitment factor) [NCBI Gene 65057] {aka DKCA6, DKCB7, PIP1, PTOP, TINT1, TPP1}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, WRN (WRN RecQ like helicase) [NCBI Gene 7486] {aka RECQ3, RECQL2, RECQL3}, PDPR (pyruvate dehydrogenase phosphatase regulatory subunit) [NCBI Gene 55066] {aka PDP3}, PTCSC2 (papillary thyroid carcinoma susceptibility candidate 2) [NCBI Gene 101928337], FOXE1 (forkhead box E1) [NCBI Gene 2304] {aka BAMLAZ, FKHL15, FOXE2, HFKH4, HFKL5, NMTC4}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, TG (thyroglobulin) [NCBI Gene 7038] {aka AITD3, TGN}
- **Diseases:** non-invasive follicular neoplasm (MESH:D009361), oncologic (MESH:D000072716), non-medullary thyroid cancer (MESH:C536914), carcinogenesis (MESH:D063646), Carney complex (MESH:D056733), PTC (MESH:D000077273), NIFTP (MESH:D018265), breast cancer (MESH:D001943), Tumor, Node, Metastasis (MESH:D008207), thyroid abnormalities (MESH:D013959), lymph node (MESH:D000072717), Werner syndrome (MESH:D014898), Gardner syndrome (MESH:D005736), FNMTC (MESH:C536911), Familial Adenomatous Polyposis (MESH:D011125), Cancer/ (MESH:D009369), ataxia-telangiectasia (MESH:D001260), lung cancer (MESH:D008175), hereditary syndromes (MESH:D009386), thyroid cancer (MESH:D013964), Cowden syndrome (MESH:D006223), node (MESH:D012804), metastases (MESH:D009362), disease (MESH:D004194)
- **Chemicals:** Radioiodine (MESH:C000614965), Celia Regina Nogueira (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.L1283P

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12944298/full.md

---
Source: https://tomesphere.com/paper/PMC12944298